Update: Costs of up to £2 bn following the Government’s advice to pharma companies to stockpile six-week supplies ahead of Brexit
In his letter addressed to the industry, the Secretary of State for Health and Social Care Matt Hancock has provided assurances that the Government is on the right path to securing a good, timely deal with the EU. However, he advised that the plans for six-week stockpile should be made by companies supplying medicines, medical devices and clinical consumables to ensure that there are no disruptions to patient care under any future circumstances.
BioIndustry Association’s (BIA) CEO Steve Bates noted that pharmaceutical companies should make a good use of the newly available channel of communication with the Department of Health; once they have received an email asking to engage with the Department, the companies will have until 10th September to formally respond to the request for information on whether they can ensure the additional medicine supply.
Matt Hancock’s letter can be found here.
Updated 29 August 2018
Following this announcement, The Guardian reported on a statement from campaign group Best for Britain, who say this stockpiling activity could cost up to £2 billion. MAP will follow the story as it develops.